Singapore markets closed

The fight against COVID19

The fight against COVID19

23.82k followers14 symbols Watchlist by TREA

Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.

Curated by TREA

TREA analyses over 100 million data points, interactions, relationships on company research and development activities, allowing investors to quickly gain insight without having to go through complex regulatory filings. Primary data sources include: US FDA (US Food and Drug Administration), US NIH (US National Institutes of Health), USPTO (US Patent and Trademark Office). The search parameters for generating this watchlist were (1) Above sector average Innovation Index score, (2) IP history of at least 5 years (3) COVID19 (4) 2019-nCov (5) SARS-CoV-2, among others.


WatchlistChange today1-month return1-year returnTotal return
The fight against COVID19-0.13%---

14 symbols

SymbolCompany nameLast priceChange% changeMarket timeVolumeAvg vol (3-month)Market cap
JNJJohnson & Johnson148.75+0.97+0.66%4:00 pm GMT-414.95M7.69M357.99B
ABBVAbbVie Inc.170.39-1.74-1.01%4:00 pm GMT-412.19M5.29M300.89B
PFEPfizer Inc.27.74--4:02 pm GMT-451.96M38.49M157.19B
SNYSanofi47.21+0.36+0.77%4:00 pm GMT-44.89M2.32M118.45B
REGNRegeneron Pharmaceuticals, Inc.1053.14+8.75+0.84%4:00 pm GMT-41.28M444.30k116.04B
GILDGilead Sciences, Inc.70.67+2.18+3.18%4:00 pm GMT-429.62M7.56M88.04B
GSKGSK plc40.48-0.28-0.69%4:00 pm GMT-43.41M3.48M83.92B
MRNAModerna, Inc.133.4-1.00-0.74%4:00 pm GMT-45.21M3.96M51.12B
TAKTakeda Pharmaceutical Company Limited12.6-0.01-0.08%4:00 pm GMT-41.69M1.62M39.76B
BNTXBioNTech SE84.64-1.24-1.44%4:00 pm GMT-41.03M712.11k20.40B
NVAXNovavax, Inc.14-0.06-0.43%4:00 pm GMT-422.81M15.65M2.06B
VIRVir Biotechnology, Inc.9.14+0.19+2.12%4:00 pm GMT-46.79M1.11M1.24B
INOInovio Pharmaceuticals, Inc.8.09+0.02+0.25%4:00 pm GMT-4371.42k337.84k209.62M
  • Yahoo Finance Video

    US indexes open mixed, pharmaceutical stocks climb: Morning Brief

    On today's episode of Morning Brief, hosts Brad Smith and Madison Mills analyze the market open and break down the biggest stories of the trading week. The major indexes (^DJI, ^IXIC, ^GSPC) opened mixed in Friday's session, with the Dow Jones Industrial Average leading gains early in the trading day. Nvidia's (NVDA) reign as the US's most valuable publicly traded company was brief. The semiconductor giant shed $118 billion in market capitalization, allowing Microsoft (MSFT) to reclaim the top spot. Moor Insights & Strategy founder, CEO, and chief analyst Patrick Moorhead emphasizes that Nvidia's continued dominance hinges on sustained enterprise demand for its offerings. If customers stop buying Nvidia's offerings, he warns, "then this whole gravy train comes to a screeching halt." Wells Fargo Investment Institute senior global market strategist Scott Wren notes that while the computer services and technology sectors are currently "very highly valued, very momentum driven," investors should consider trimming some of their gains in these areas and reallocating into sectors like industrials, energy, and healthcare. The pharmaceutical and biotech sectors are making major moves as Sarepta (SRPT) received expanded approval from the Food and Drug Administration for its muscular dystrophy drug, and Gilead (GILD) saw encouraging results from its twice-yearly shot to prevent HIV. Meanwhile, Oppenheimer has upgraded Nike (NKE) from Perform to Outperform and raised its price target from $110 to $120. Meta (META) also received a bullish call, as KeyBanc raised its price target from $475 to $540, citing sustained advertising momentum. Keybanc Managing Director Justin Patterson explains that Meta's ad revenue is "accelerating sequentially" despite intensifying competition, indicating that "demand for Meta's advertisements remains very high." This post was written by Melanie Riehl

  • Investor's Business Daily

    Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy

    Sarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its Duchenne muscular dystrophy gene therapy more than tenfold, according to one estimate.

  • Business Wire

    Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

    OSAKA, Japan & CAMBRIDGE, Mass., June 21, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to tr